DOP2011000114A - “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas - Google Patents

“compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas

Info

Publication number
DOP2011000114A
DOP2011000114A DO2011000114A DO2011000114A DOP2011000114A DO P2011000114 A DOP2011000114 A DO P2011000114A DO 2011000114 A DO2011000114 A DO 2011000114A DO 2011000114 A DO2011000114 A DO 2011000114A DO P2011000114 A DOP2011000114 A DO P2011000114A
Authority
DO
Dominican Republic
Prior art keywords
compounds
purin
stem cells
hematopoietic stem
aminoalkyl compounds
Prior art date
Application number
DO2011000114A
Other languages
English (en)
Inventor
Wang Xing
Boitano Anthony
Cooke Michael
Pan Shifeng
G Schultz Peter
Tellew John
Wan Yongqin
Original Assignee
Novartis Ag
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000114(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag
Publication of DOP2011000114A publication Critical patent/DOP2011000114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a compuestos y composiciones para expandir el número de células CD34+ para su uso en transplantes autólogos o alogénicos para el tratamiento de pacientes con inmunodeficiencia y enfermedades autoinmunitarias heredadas y diversos trastornos hematopoyéticos, para reconstituir las líneas celulares hematopoyéticas y las defensas del sistema inmunitario. Los compuestos de la invención son capaces de regular a la baja la actividad y/o la expresión del receptor de hidrocarburos de arilo y/o un efector corriente abajo de la ruta del receptor de hidrocarburos de arilo. Particularmente, la presente invención se refiere a compuestos 9H-purina-6-aminoalquil de fórmula 1a: por ejemplo, el compuesto con la siguiente fórmula:
DO2011000114A 2008-10-30 2011-04-28 “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas DOP2011000114A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10982108P 2008-10-30 2008-10-30
US24276509P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
DOP2011000114A true DOP2011000114A (es) 2017-09-29

Family

ID=42111339

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000114A DOP2011000114A (es) 2008-10-30 2011-04-28 “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas

Country Status (41)

Country Link
US (4) US8927281B2 (es)
EP (2) EP3524604B1 (es)
JP (1) JP5390626B2 (es)
KR (1) KR101434719B1 (es)
CN (1) CN102203096B (es)
AR (1) AR074063A1 (es)
AU (1) AU2009317898B2 (es)
BR (1) BRPI0921799B8 (es)
CA (3) CA2943540C (es)
CL (2) CL2009002010A1 (es)
CO (1) CO6410309A2 (es)
CR (1) CR20110192A (es)
CU (1) CU24495B1 (es)
CY (1) CY1121857T1 (es)
DK (1) DK2350078T3 (es)
DO (1) DOP2011000114A (es)
EA (1) EA019872B1 (es)
EC (1) ECSP11011090A (es)
ES (2) ES2948567T3 (es)
GE (1) GEP20146053B (es)
HN (1) HN2011001195A (es)
HR (1) HRP20191238T1 (es)
HU (1) HUE044802T2 (es)
IL (1) IL212368A (es)
JO (1) JO3593B1 (es)
LT (1) LT2350078T (es)
MA (1) MA32828B1 (es)
MX (1) MX347834B (es)
MY (1) MY155137A (es)
NI (1) NI201100083A (es)
NZ (1) NZ592435A (es)
PE (1) PE20100362A1 (es)
PL (1) PL2350078T3 (es)
PT (1) PT2350078T (es)
RS (1) RS59027B1 (es)
SI (1) SI2350078T1 (es)
SM (1) SMP201100024B (es)
SV (1) SV2011003888A (es)
TN (1) TN2011000174A1 (es)
TW (1) TWI532486B (es)
WO (1) WO2010059401A2 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
UA98482C2 (ru) * 2007-03-28 2012-05-25 Ньюросерч А/С Пуринильные производные и их применение в качестве модуляторов каналов калия
US20100152210A1 (en) 2007-03-28 2010-06-17 Neuro Search A/S/ Purinyl derivatives and their use as potassium channel modulators
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010034707A1 (en) * 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2012074068A1 (ja) 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
JP2014523741A (ja) * 2011-07-06 2014-09-18 セレラント セラピューティクス インコーポレイテッド 血小板産生のための巨核球前駆細胞
US20140328811A1 (en) * 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
EP2753315B1 (en) * 2011-09-07 2017-03-01 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
CA2858069C (en) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
AU2013212457B2 (en) 2012-01-27 2017-02-16 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
EP2814951B1 (en) 2012-02-13 2019-04-03 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
US9567569B2 (en) * 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
CA2897499A1 (en) 2013-01-08 2014-07-17 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US9757378B2 (en) * 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
US10617721B2 (en) * 2013-10-24 2020-04-14 Ospedale San Raffaele S.R.L. Methods for genetic modification of stem cells
SG10201803533YA (en) 2013-10-31 2018-06-28 Hutchinson Fred Cancer Res Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
JP6734283B2 (ja) 2015-01-21 2020-08-05 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
WO2016176651A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2018004600A (es) * 2015-10-15 2019-09-04 Celularity Inc Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN108463548B (zh) 2015-10-30 2023-04-18 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
US20190010495A1 (en) * 2015-12-28 2019-01-10 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
KR102542533B1 (ko) 2016-04-14 2023-06-13 프레드 허친슨 캔서 센터 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법
CA3023239A1 (en) * 2016-05-07 2017-11-16 Celularity Inc. Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
WO2017202816A1 (en) 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
WO2018048346A1 (en) * 2016-08-18 2018-03-15 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
CN109844126A (zh) 2016-09-28 2019-06-04 诺华股份有限公司 基于多孔膜的大分子递送系统
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
US10457683B2 (en) * 2017-04-12 2019-10-29 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
EP3612030A4 (en) * 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES
CA3059755A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
MX2020001261A (es) * 2017-08-02 2020-08-17 Univ Northwestern Compuestos de pirimidina fusionada sustituida y usos de los mismos.
US20200246393A1 (en) 2017-09-28 2020-08-06 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
CA3077391A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. In vitro method of mrna delivery using lipid nanoparticles
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
WO2019101641A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
WO2019101647A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
CA3082856A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US11591311B2 (en) 2017-11-21 2023-02-28 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
BR112020011186A2 (pt) 2017-12-06 2020-11-17 Magenta Therapeutics, Inc. regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2019156989A1 (en) * 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
US20220340875A1 (en) * 2018-07-19 2022-10-27 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
BR112021003529A2 (pt) 2018-08-24 2021-05-18 Jaguahr Therapeutics Pte Ltd derivados de tetra-hidropiridopirimidina como moduladores de ahr
EP3843853A1 (en) 2018-08-31 2021-07-07 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
EP3847176A1 (en) 2018-09-07 2021-07-14 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
EP4268831A3 (en) 2018-09-12 2024-05-22 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
WO2020081636A1 (en) * 2018-10-16 2020-04-23 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
EP3874027A4 (en) * 2018-10-31 2022-08-10 Magenta Therapeutics, Inc. PROCEDURE FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANTATION THERAPY
PE20220967A1 (es) * 2019-08-12 2022-06-10 Bayer Ag [1,2,4] triazolo [1,5-c] quinazolin-5-aminas
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN115279764A (zh) 2019-11-26 2022-11-01 医肯纳肿瘤学公司 多晶型咔唑衍生物及其用途
JP2023505366A (ja) 2019-12-09 2023-02-08 大塚製薬株式会社 アクリルアミド化合物
EP4077676A1 (en) 2019-12-18 2022-10-26 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
AU2021226411A1 (en) 2020-02-26 2022-09-22 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of AhR signalling
JP2023525513A (ja) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム 細胞ゲノムにおける外因性配列の標的化挿入のための方法
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US20230279440A1 (en) 2020-05-06 2023-09-07 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
EP4177337A1 (en) 2020-07-01 2023-05-10 Nextgem Inc. Human long-term hematopoietic stem cell marker
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
EP4359527A2 (en) 2021-06-23 2024-05-01 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
WO2023150393A2 (en) 2022-02-07 2023-08-10 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399196A (en) 1959-01-22 1968-08-27 Ciba Geigy Corp Nu-substituted pyrazolo-pyrimidines
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
ATE159257T1 (de) 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
TR200102714T2 (tr) * 1999-02-01 2002-01-21 Cv Therapeutics, Inc. Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CN1110552C (zh) * 1999-07-13 2003-06-04 中国人民解放军第二军医大学 一种体外扩增造血干细胞的新方法
ES2256038T3 (es) 1999-09-10 2006-07-16 Smithkline Beecham Corporation Mimeticos de trombopoyetina.
US6552008B1 (en) 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
DE60031714T2 (de) 1999-12-06 2007-09-06 Smithkline Beecham Corp. Thrombopoietin-mimetika
DE60028253T2 (de) 1999-12-17 2007-03-08 Ariad Pharmaceuticals, Inc., Cambridge Neue purine
CZ20022353A3 (cs) * 2000-01-07 2003-02-12 Universitaire Instelling Antwerpen Deriváty purinu, způsob jejich přípravy a jejich použití
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU7107301A (en) * 2000-07-18 2002-01-30 Nichimo Co. Ltd. Stem cell reinforcing material
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
CA2439471A1 (en) 2001-12-28 2003-07-17 Daiichi Suntory Pharma Co., Ltd. Promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2004089068A (ja) * 2002-08-30 2004-03-25 Kobe University Ａｈ受容体リガンド特異的な遺伝子発現誘導因子及びその機能に基づく異種遺伝子誘導発現系の利用技術
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005026164A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Pharmacologically active imidazo[4,5-c]pyridines
EP1715871A1 (en) 2003-12-22 2006-11-02 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
CA2578993A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005288858B2 (en) * 2004-09-30 2011-04-21 Janssen R&D Ireland HCV inhibiting bi-cyclic pyrimidines
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1824850A2 (en) * 2004-12-09 2007-08-29 Nycomed GmbH SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION
WO2006118914A2 (en) 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
CN101213190A (zh) 2005-07-14 2008-07-02 Irm责任有限公司 用作tpo模拟物的化合物和组合物
AU2006279537A1 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as TPO mimetics
PL2322525T3 (pl) * 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
WO2007149548A2 (en) * 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
WO2008051502A1 (en) 2006-10-19 2008-05-02 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
US20100152210A1 (en) * 2007-03-28 2010-06-17 Neuro Search A/S/ Purinyl derivatives and their use as potassium channel modulators
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity

Also Published As

Publication number Publication date
CA2740589C (en) 2017-11-21
US20170239296A1 (en) 2017-08-24
HUE044802T2 (hu) 2019-11-28
WO2010059401A2 (en) 2010-05-27
LT2350078T (lt) 2019-07-25
KR101434719B1 (ko) 2014-08-27
CU24495B1 (es) 2021-01-12
NI201100083A (es) 2011-11-03
JP2012507554A (ja) 2012-03-29
US20100183564A1 (en) 2010-07-22
SMP201100024B (it) 2012-03-05
IL212368A0 (en) 2011-06-30
US8927281B2 (en) 2015-01-06
IL212368A (en) 2015-02-26
AU2009317898A1 (en) 2010-05-27
AU2009317898B2 (en) 2013-07-11
US20210187033A1 (en) 2021-06-24
ECSP11011090A (es) 2011-09-30
CL2013001874A1 (es) 2014-04-04
CO6410309A2 (es) 2012-03-30
MY155137A (en) 2015-09-15
PT2350078T (pt) 2019-07-19
SI2350078T1 (sl) 2019-08-30
CA2943540C (en) 2020-10-27
BRPI0921799A2 (pt) 2016-01-12
TWI532486B (zh) 2016-05-11
EP3524604A1 (en) 2019-08-14
US20140114070A1 (en) 2014-04-24
CA2740589A1 (en) 2010-05-27
US9580426B2 (en) 2017-02-28
GEP20146053B (en) 2014-03-10
MX347834B (es) 2016-10-07
DK2350078T3 (da) 2019-07-15
CA2943540A1 (en) 2010-05-27
HRP20191238T1 (hr) 2019-11-29
PL2350078T3 (pl) 2019-09-30
AR074063A1 (es) 2010-12-22
NZ592435A (en) 2013-01-25
RS59027B1 (sr) 2019-08-30
ES2948567T3 (es) 2023-09-14
CL2009002010A1 (es) 2010-06-25
TW201028153A (en) 2010-08-01
CN102203096B (zh) 2014-09-17
WO2010059401A3 (en) 2010-09-23
BRPI0921799B8 (pt) 2021-05-25
MA32828B1 (fr) 2011-11-01
CN102203096A (zh) 2011-09-28
JO3593B1 (ar) 2020-07-05
HN2011001195A (es) 2014-01-13
CA3061937A1 (en) 2010-05-27
TN2011000174A1 (en) 2012-12-17
EP3524604B1 (en) 2023-03-29
SV2011003888A (es) 2011-07-05
CU20110096A7 (es) 2012-01-31
EA201100663A1 (ru) 2011-12-30
BRPI0921799B1 (pt) 2020-09-29
PE20100362A1 (es) 2010-05-27
EP2350078A2 (en) 2011-08-03
CR20110192A (es) 2011-06-10
JP5390626B2 (ja) 2014-01-15
CY1121857T1 (el) 2020-07-31
MX2011004593A (es) 2011-06-16
SMAP201100024A (it) 2011-07-11
KR20110075042A (ko) 2011-07-05
ES2736728T3 (es) 2020-01-07
EA019872B1 (ru) 2014-06-30
EP2350078B1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
DOP2011000114A (es) “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
BR112017005390A2 (pt) células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY33616A (es) Compuestos con estructura de imidazotriazinona
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
PE20151495A1 (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2011002180A1 (es) Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor.
AR094026A1 (es) Metodo para activar la celula t helper
BR112013028306A2 (pt) plantas com características úteis e processos relacionados
BR112013026501A2 (pt) “métodos para preparar um oócito, de fertilização in vitro, e para aumentar a capacidade de geração de atp de um oócito, oócito, e, composição”
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
ECSP15013883A (es) Benzamidas
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
BR112012026007A2 (pt) método e composições para a inibição de células treg, bem como uso de células th1 alogênicas e uma fonte de antígenos
AR084197A1 (es) Composicion para uso topico para el tratamiento de trastornos de la piel
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.